Advertisement

Journal of Gastroenterology

, Volume 53, Issue 8, pp 959–966 | Cite as

Statin use and pancreatic cancer risk in two prospective cohort studies

  • Tsuyoshi Hamada
  • Natalia Khalaf
  • Chen Yuan
  • Ana Babic
  • Vicente Morales-Oyarvide
  • Zhi Rong Qian
  • Jonathan Andrew Nowak
  • Kimmie Ng
  • Peter Kraft
  • Douglas Adam Rubinson
  • Meir Jonathan Stampfer
  • Edward Luciano Giovannucci
  • Charles Stewart Fuchs
  • Shuji Ogino
  • Brian Matthew Wolpin
Original Article—Liver, Pancreas, and Biliary Tract

Abstract

Background

Statins, 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, are common lipid-lowering agents and may reduce the risk of several cancer types including pancreatic cancer. However, the association between statin use and pancreatic cancer risk has not been fully evaluated in prospective studies.

Methods

We studied the association between statin use and incident pancreatic cancer in 113,059 participants from the prospective Nurses’ Health Study and Health Professionals Follow-up Study. Statin use was self-reported via study questionnaires and updated biennially. Hazard ratios (HRs) and 95% confidence intervals (CIs) for incidence of pancreatic cancer were estimated using multivariable Cox proportional hazards models with adjustment for potential confounders.

Results

In total, 583 participants developed incident pancreatic cancer during 1.4 million person-years of follow-up. No difference was identified in pancreatic cancer risk for regular versus non-regular statin users (multivariable-adjusted HR 0.98; 95% CI 0.82–1.16). There was no significant heterogeneity in the association of statin use with pancreatic cancer risk between the cohorts. Similarly, longer duration of regular statin use was not associated with decreased risk of pancreatic cancer (Ptrend = 0.65). The results remained similar when we examined statin use status at baseline or accounting for 4-year latency period. We observed no statistically significant effect modification for the association of statin use with pancreatic cancer risk by body mass index, smoking status, or diabetes mellitus status (all Pinteraction > 0.21).

Conclusions

Regular statin use was not associated with pancreatic cancer risk in two large prospective cohort studies in the U.S.

Keywords

Chemoprevention Cohort studies Hydroxymethylglutaryl-CoA reductase inhibitors Pancreatic neoplasms Risk factors 

Notes

Acknowledgements

The Nurses’ Health Study is supported by U.S. National Institutes of Health (NIH) Grants: UM1 CA186107, P01 CA87969, and R01 CA49449. The Health Professionals Follow-up Study is supported by NIH UM1 CA167552. This work was additionally supported by NIH R01 CA205406 and the Broman Fund for Pancreatic Cancer Research to K.N.; by the Robert T. and Judith B. Hale Fund for Pancreatic Cancer, Perry S. Levy Fund for Gastrointestinal Cancer Research, Pappas Family Research Fund for Pancreatic Cancer, NIH R01 CA124908, and NIH P50 CA127003 to C.S.F.; by NIH R35 CA197735 to S.O.; and by Hale Center for Pancreatic Cancer Research, NIH/National Cancer Institute (NCI) U01 CA210171, Department of Defense CA130288, Lustgarten Foundation, Pancreatic Cancer Action Network, Noble Effort Fund, Peter R. Leavitt Family Fund, Wexler Family Fund, and Promises for Purple to B.M.W. T.H. was supported by a fellowship grant from the Mitsukoshi Health and Welfare Foundation. The content is solely the responsibility of the authors and does not necessarily represent the official views of NIH. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors would like to thank the participants and staff of the Nurses’ Health Study and the Health Professionals Follow-up Study for their valuable contributions as well as the following state cancer registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, WY. The authors assume full responsibility for analyses and interpretation of the data.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

535_2018_1430_MOESM1_ESM.docx (57 kb)
Supplementary material 1 (DOCX 57 kb)

References

  1. 1.
    Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67:7–30.CrossRefPubMedGoogle Scholar
  2. 2.
    Gazzerro P, Proto MC, Gangemi G, et al. Pharmacological actions of statins: a critical appraisal in the management of cancer. Pharmacol Rev. 2012;64:102–46.CrossRefPubMedGoogle Scholar
  3. 3.
    Demierre MF, Higgins PD, Gruber SB, et al. Statins and cancer prevention. Nat Rev Cancer. 2005;5:930–42.CrossRefPubMedGoogle Scholar
  4. 4.
    Gronich N, Rennert G. Beyond aspirin-cancer prevention with statins, metformin and bisphosphonates. Nat Rev Clin Oncol. 2013;10:625–42.CrossRefPubMedGoogle Scholar
  5. 5.
    Pisanti S, Picardi P, Ciaglia E, et al. Novel prospects of statins as therapeutic agents in cancer. Pharmacol Res. 2014;88:84–98.CrossRefPubMedGoogle Scholar
  6. 6.
    Matusewicz L, Meissner J, Toporkiewicz M, et al. The effect of statins on cancer cells–review. Tumour Biol. 2015;36:4889–904.CrossRefPubMedGoogle Scholar
  7. 7.
    Mullen PJ, Yu R, Longo J, et al. The interplay between cell signalling and the mevalonate pathway in cancer. Nat Rev Cancer. 2016;16:718–31.CrossRefPubMedGoogle Scholar
  8. 8.
    Miller MS, Allen P, Brentnall TA, et al. Pancreatic cancer chemoprevention translational workshop: meeting report. Pancreas. 2016;45:1080–91.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Chen MJ, Tsan YT, Liou JM, et al. Statins and the risk of pancreatic cancer in type 2 diabetic patients—a population-based cohort study. Int J Cancer. 2016;138:594–603.CrossRefPubMedGoogle Scholar
  10. 10.
    Carey FJ, Little MW, Pugh TF, et al. The differential effects of statins on the risk of developing pancreatic cancer: a case–control study in two centres in the United Kingdom. Dig Dis Sci. 2013;58:3308–12.CrossRefPubMedGoogle Scholar
  11. 11.
    Khurana V, Sheth A, Caldito G, et al. Statins reduce the risk of pancreatic cancer in humans: a case–control study of half a million veterans. Pancreas. 2007;34:260–5.CrossRefPubMedGoogle Scholar
  12. 12.
    Cui X, Xie Y, Chen M, et al. Statin use and risk of pancreatic cancer: a meta-analysis. Cancer Causes Control. 2012;23:1099–111.CrossRefPubMedGoogle Scholar
  13. 13.
    Birmann BM, Barnard ME, Bertrand KA, et al. Nurses’ health study contributions on the epidemiology of less common cancers: endometrial, ovarian, pancreatic, and hematologic. Am J Public Health. 2016;106:1608–15.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Giovannucci E, Ascherio A, Rimm EB, et al. Physical activity, obesity, and risk for colon cancer and adenoma in men. Ann Intern Med. 1995;122:327–34.CrossRefPubMedGoogle Scholar
  15. 15.
    Bao Y, Nimptsch K, Wolpin BM, et al. Dietary insulin load, dietary insulin index, and risk of pancreatic cancer. Am J Clin Nutr. 2011;94:862–8.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Bao Y, Ng K, Wolpin BM, et al. Predicted vitamin D status and pancreatic cancer risk in two prospective cohort studies. Br J Cancer. 2010;102:1422–7.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Cao Y, Nishihara R, Wu K, et al. Population-wide impact of long-term use of aspirin and the risk for cancer. JAMA Oncol. 2016;2:762–9.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Rich-Edwards JW, Corsano KA, Stampfer MJ. Test of the National Death Index and Equifax Nationwide Death Search. Am J Epidemiol. 1994;140:1016–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Lee JE, Baba Y, Ng K, et al. Statin use and colorectal cancer risk according to molecular subtypes in two large prospective cohort studies. Cancer Prev Res (Phila). 2011;4:1808–15.CrossRefGoogle Scholar
  20. 20.
    Tsai CJ, Leitzmann MF, Willett WC, et al. Statin use and the risk of cholecystectomy in women. Gastroenterology. 2009;136:1593–600.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Yachida S, Jones S, Bozic I, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature. 2010;467:1114–7.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Chen Y, Wu F, Saito E, et al. Association between type 2 diabetes and risk of cancer mortality: a pooled analysis of over 771,000 individuals in the Asia Cohort Consortium. Diabetologia. 2017;60:1022–32.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10:101–29.CrossRefGoogle Scholar
  24. 24.
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Fendrich V, Sparn M, Lauth M, et al. Simvastatin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer. Pancreatology. 2013;13:502–7.CrossRefPubMedGoogle Scholar
  26. 26.
    Liao J, Chung YT, Yang AL, et al. Atorvastatin inhibits pancreatic carcinogenesis and increases survival in LSL-KrasG12D-LSL-Trp53R172H-Pdx1-Cre mice. Mol Carcinog. 2013;52:739–50.CrossRefPubMedGoogle Scholar
  27. 27.
    Biankin AV, Waddell N, Kassahn KS, et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature. 2012;491:399–405.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Mohammed A, Qian L, Janakiram NB, et al. Atorvastatin delays progression of pancreatic lesions to carcinoma by regulating PI3/AKT signaling in p48Cre/+ LSL-KrasG12D/+ mice. Int J Cancer. 2012;131:1951–62.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Corcos L, Le Jossic-Corcos C. Statins: perspectives in cancer therapeutics. Dig Liver Dis. 2013;45:795–802.CrossRefPubMedGoogle Scholar
  30. 30.
    Thurnher M, Nussbaumer O, Gruenbacher G. Novel aspects of mevalonate pathway inhibitors as antitumor agents. Clin Cancer Res. 2012;18:3524–31.CrossRefPubMedGoogle Scholar
  31. 31.
    Jacobs EJ, Newton CC, Thun MJ, et al. Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort. Cancer Res. 2011;71:1763–71.CrossRefPubMedGoogle Scholar
  32. 32.
    Simon MS, Desai P, Wallace R, et al. Prospective analysis of association between statins and pancreatic cancer risk in the Women’s Health Initiative. Cancer Causes Control. 2016;27:415–23.CrossRefPubMedGoogle Scholar
  33. 33.
    Jeon CY, Pandol SJ, Wu B, et al. The association of statin use after cancer diagnosis with survival in pancreatic cancer patients: a SEER-Medicare analysis. PLoS One. 2015;10:e0121783.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Wu BU, Chang J, Jeon CY, et al. Impact of statin use on survival in patients undergoing resection for early-stage pancreatic cancer. Am J Gastroenterol. 2015;110:1233–9.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Gbelcova H, Lenicek M, Zelenka J, et al. Differences in antitumor effects of various statins on human pancreatic cancer. Int J Cancer. 2008;122:1214–21.CrossRefPubMedGoogle Scholar
  36. 36.
    Huang BZ, Chang JI, Li E, et al. Influence of statins and cholesterol on mortality among patients with pancreatic cancer. J Natl Cancer Inst. 2017;109:djw275.CrossRefPubMedGoogle Scholar
  37. 37.
    Lee HS, Lee SH, Lee HJ, et al. Statin use and its impact on survival in pancreatic cancer patients. Med (Baltimore). 2016;95:e3607.CrossRefGoogle Scholar

Copyright information

© Japanese Society of Gastroenterology 2018

Authors and Affiliations

  • Tsuyoshi Hamada
    • 1
  • Natalia Khalaf
    • 2
  • Chen Yuan
    • 3
    • 4
  • Ana Babic
    • 3
  • Vicente Morales-Oyarvide
    • 3
  • Zhi Rong Qian
    • 1
  • Jonathan Andrew Nowak
    • 5
  • Kimmie Ng
    • 3
  • Peter Kraft
    • 4
    • 6
  • Douglas Adam Rubinson
    • 3
  • Meir Jonathan Stampfer
    • 4
    • 7
    • 8
  • Edward Luciano Giovannucci
    • 4
    • 7
    • 8
  • Charles Stewart Fuchs
    • 9
    • 10
    • 11
  • Shuji Ogino
    • 1
    • 4
    • 5
  • Brian Matthew Wolpin
    • 3
  1. 1.Department of Oncologic PathologyDana-Farber Cancer Institute and Harvard Medical SchoolBostonUSA
  2. 2.Division of Gastroenterology, Hepatology, and EndoscopyBrigham and Women’s Hospital and Harvard Medical SchoolBostonUSA
  3. 3.Department of Medical OncologyDana-Farber Cancer Institute and Harvard Medical SchoolBostonUSA
  4. 4.Department of EpidemiologyHarvard T.H. Chan School of Public HealthBostonUSA
  5. 5.Program in MPE Molecular Pathological Epidemiology, Department of PathologBrigham and Women’s Hospital and Harvard Medical SchoolBostonUSA
  6. 6.Department of BiostatisticsHarvard T.H. Chan School of Public HealthBostonUSA
  7. 7.Channing Division of Network Medicine, Department of MedicineBrigham and Women’s Hospital and Harvard Medical SchoolBostonUSA
  8. 8.Department of NutritionHarvard T.H. Chan School of Public HealthBostonUSA
  9. 9.Yale Cancer CenterNew HavenUSA
  10. 10.Department of MedicineYale School of MedicineNew HavenUSA
  11. 11.Smilow Cancer HospitalNew HavenUSA

Personalised recommendations